



17W 16734 21

PATENT  
ATTORNEY DOCKET NO. 50125/019001

Certificate of Mailing: Date of Deposit: January 22, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Guy Beardsley

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hallek et al.

Confirmation No.: 8894

Serial No.: 09/720,066

Art Unit: 1633

Filed: October 19, 2001

Examiner: Marvich, Maria.

Customer No.: 21559

Title: AAV SCLEROPROTEIN, ITS PREPARATION AND USE

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

01/25/2007 SSITHIB1 00000062 09720066

01 FC:1806

180.00 0P


5

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 22 Jan 2007

  
\_\_\_\_\_  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

Sheet 1 of 3

|  |                     |                  |
|--|---------------------|------------------|
| SUBSTITUTE FORM PTO-1449<br>(MODIFIED)<br><br>U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE<br><br>INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT<br>(Use several sheets if necessary)<br><br>(37 C.F.R. § 1.98(b)) | Attorney Docket No. | 50125/019001     |
|  | Serial No.          | 09/720,066       |
|  | Applicant           | Hallek et al.    |
|  | Filing Date         | October 19, 2001 |
|  | Group               | 1633             |
|  | IDS Filed           | January 22, 2007 |

| U.S. PATENT DOCUMENTS |                 |                  |                       |
|-----------------------|-----------------|------------------|-----------------------|
| Examiner's Initials   | Document Number | Publication Date | Patentee or Applicant |
|                       | 2001/031463     | 10/18/01         | Kleinschmidt et al.   |
|                       | 2002/0192823    | 12/19/02         | Bartlett et al.       |
|                       | 5,276,136       | 01/04/94         | Skubitz et al.        |
|                       | 6,491,907       | 12/10/02         | Rabinowitz et al.     |

| FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION |                 |                  |                          |                      |
|--|-----------------|------------------|--------------------------|----------------------|
| Examiner's Initials                                    | Document Number | Publication Date | Country or Patent Office | Translation (Yes/No) |
|  |                 |                  |                          |                      |

| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) |  |
|---|--|
|   | Anderson, "Human Gene Therapy," <i>Nature</i> 392:25-30 (1998).  |
|   | Asokan et al., "AAV Does the Shuffle," <i>Nature Biotechnology</i> 24:158-160 (2006).  |
|   | Buning et al., "Receptor Targeting of Adeno-Associated Virus Vectors," <i>Gene Therapy</i> 10:1142-1151 (2003).  |
|   | Grifman et al., "Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-Associated Virus Capsids," <i>Molecular Therapy</i> 3:964-975 (2001).  |
|   | Hoque et al., "Nuclear Transport of the Major Capsid Protein is Essential for Adeno-Associated Virus Capsid Formation," <i>Journal of Virology</i> 73:7912-7915 (1999).  |
|   | Huttner et al., "Genetic Modifications of the Adeno-Associated Virus Type 2 Capsid Reduce the Affinity and the Neutralizing Effects of Human Serum Antibodies," <i>Gene Therapy</i> 10:2139-2147 (2003).   |
|   | Kmieciak, "Gene Therapy," <i>American Scientist</i> 87:240-247 (1999).   |
|   | Maass et al., "Recombinant Adeno-Associated Virus for the Generation of Autologous, Gene-Modified Tumor Vaccines: Evidence for a High Transduction Efficiency into Primary Epithelial Cancer Cells," <i>Human Gene Therapy</i> 9:1049-1059 (1998). |

|   |                 |
|---|-----------------|
| EXAMINER  | DATE CONSIDERED |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. |                 |



|  |                     |                  |
|--|---------------------|------------------|
| SUBSTITUTE FORM PTO-1449<br>(MODIFIED)<br><br>U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE<br><br>INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT<br>(Use several sheets if necessary)<br><br>(37 C.F.R. § 1.98(b)) | Attorney Docket No. | 50125/019001     |
|  | Serial No.          | 09/720,066       |
|  | Applicant           | Hallek et al.    |
|  | Filing Date         | October 19, 2001 |
|  | Group               | 1633             |
|  | IDS Filed           | January 22, 2007 |

| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)   |   |
|---|---|
|   | Maheshri et al., "Directed Evolution of Adeno-Associated Virus Yields Enhanced Gene Delivery Vectors," <i>Nature Biotechnology</i> 24:198-204 (2006).   |
|   | Marshall, "Second Child in French Trial is Found to Have Leukemia," <i>Science</i> 299:320 (2003).  |
|   | Meng et al., "Tumor Suppressor Genes as Targets for Cancer Gene Therapy," <i>Gene Therapy of Cancer Chapter 1</i> , pp. 3-18 (1999).  |
|   | Mizukami et al., "Adeno-Associated Virus Type 2 Binds to a 150-Kilodalton Cell Membrane Glycoprotein," <i>Virology</i> 217:124-130 (1996).  |
|   | Moskalenko et al., "Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure," <i>Journal of Virology</i> 74:1761-1766 (2000).                |
|   | Nicklin et al., "Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells," <i>Molecular Therapy</i> 4:174-181 (2001).  |
|   | Perabo et al., "In Vitro Selection of Viral Vectors with Modified Tropism: The Adeno-Associated Virus Display," <i>Molecular Therapy</i> 8:151-157 (2003).  |
|   | Qing et al., "Human Fibroblast Growth Factor Receptor 1 is a Co-Receptor for Infection by Adeno-Associated Virus 2," <i>Nature Medicine</i> 5:71-77 (1999).   |
|   | Ried et al., "Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vectors Retargeting to Specific Cell Surface Receptors," <i>Journal of Virology</i> 76:4559-4566 (2002).    |
|   | Russell, "Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects," <i>European Journal of Cancer</i> 30A:1165-1171 (1994).  |
|   | Shi et al., "Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface Receptors," <i>Human Gene Therapy</i> 12:1697-1711 (2001). |
|   | Shi et al., "RGD Inclusion of VP3 Provides Adeno-Associated Virus Type 2 (AAV2)-Based Vectors with a Heparan Sulfate-Independent Cell Entry Mechanism," <i>Molecular Therapy</i> 7:515-525 (2003).                          |
|   | Smith et al., "The Challenges of genome Sequence Annotation or "the Devil is in the Details," <i>Nature Biotechnology</i> , 15:1222-1223 (1997).  |
|   | Spear et al., "Evidence for Two Nucleotide Sequence Orientations Within the Terminal Repetition of Adeno-Associated Virus DNA," <i>Journal of Virology</i> 24:627-634 (1977).   |
|   | Starovasnik et al., "Structural Mimicry of a Native Protein by a Minimized Binding Domain," <i>Proc. Natl. Acad. Sci. USA</i> 94:10080-10085 (1997).  |
|   | Summerford et al., "Membrane Associated Heparan Sulfate Proteoglycan is a Receptor for Adeno-Associated Virus Type 2 Virions," <i>Journal of Virology</i> 72:1438-1445 (1998).  |
| EXAMINER  | DATE CONSIDERED   |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. |   |



|  |                     |                  |
|--|---------------------|------------------|
| SUBSTITUTE FORM PTO-1449<br>(MODIFIED)<br><br>U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE<br><br>INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT<br>(Use several sheets if necessary)<br><br>(37 C.F.R. § 1.98(b)) | Attorney Docket No. | 50125/019001     |
|  | Serial No.          | 09/720,066       |
|  | Applicant           | Hallek et al.    |
|  | Filing Date         | October 19, 2001 |
|  | Group               | 1633             |
|  | IDS Filed           | January 22, 2007 |

| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) |  |
|---|--|
|   | Summerford et al., "αVβ5 Integrin: A Co-receptor for Adeno-Associated Virus Type 2 Infection," <i>Nature Medicine</i> 5:78-82 (1999).  |
|   | Tseng et al., "Evolutionary Model for Predicting Protein Function by Matching Local Surfaces: a Bayesian Monte Carlo Approach," The Ninth Annual Conference on Research in Computational Molecular Biology, May 14-18, 2005  |
|   | Verma et al., "Gene Therapy-Promises, Problems and Prospects," <i>Nature</i> 389:239-242 (1997).   |
|   | Wendtner et al., "Efficient Gene Transfer of CD40 Ligand into Primary B-CLL cells using recombinant Adeno-Associated Virus (rAAV) Vectors," <i>Blood</i> 100:1655-1661 (2002).   |
|   | White et al., "Designer" Gene Therapy May Target Specific Body Area," <i>Business News</i> 2:1-2 (2003).   |
|   | White et al., "Targeted Gene Delivery to Vascular Tissue in Vivo by Tropism-Modified Adeno-Associated Virus Vectors," <i>Circulation</i> 109:513-519 (2004).   |
|   | Wobus et al., "Monoclonal Antibodies Against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infection," <i>Journal of Virology</i> 74:9281-9293 (2000). |
|   | Wu et al., "Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism," <i>Journal of Virology</i> 74:8635-8647 (2000).  |

|   |                 |
|---|-----------------|
| EXAMINER  | DATE CONSIDERED |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. |                 |